Multiple myeloma: practice patterns across Europe.
Real-world data describing management of patients with multiple myeloma are limited. A European (Belgium, France, Germany, Italy, Spain, Switzerland, UK) observational chart review was conducted to address this. Physicians completed questionnaires for every patient seen during a 2-4-week observation period, regardless of treatment status. A total of 435 physicians completed 7635 cross-sectional chart reviews. Overall, 47% of patients were undergoing anti-tumour drug treatment, 42% had previously received ≥1 line of treatment and 12% had never received anti-tumour drug treatment. Of the patients treated by oncologists, onco-haematologists or internists, 95% received, or were expected to receive, at least one line of anti-tumour drug treatment, 61% received ≥2 lines of therapy and 38% received ≥3 lines. Except in the UK, the most commonly used induction therapies contained bortezomib (48%); lenalidomide was the most commonly used first-line maintenance therapy (45%) and second- and third-line agent overall (60% and 52% of patients at those lines, respectively). Bortezomib retreatment was used in 47% of patients who received it first line. Treatment patterns became more diverse with subsequent treatment lines. This study provides insight into real-world treatment patterns in Europe. While treatment practices are broadly similar across countries, some notable differences in the agents used exist.
Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany. marc.raab@med.uni-heidelberg.de.
Marc S
0000-0003-4181-6922
MS
Raab
"Seràgnoli" Institute of Haematology and Medical Oncology, Bologna University School of Medicine, Bologna, Italy.
Michele
M
Cavo
Department of Haematology, UZ Leuven, Leuven, Belgium.
Michel
M
Delforge
Department of Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland.
Christoph
C
Driessen
Kantar Health, Montrouge, France.
Leah
L
Fink
Kantar Health, Montrouge, France.
Alain
A
Flinois
Amgen (Europe) GmbH, Zug, Switzerland.
Sebastian
S
Gonzalez-McQuire
Amgen (Europe) GmbH, Zug, Switzerland.
Reza
R
Safaei
Centre Hospitalier Lyon Sud, Lyon, France.
Lionel
L
Karlin
Haematology Service, University Hospital Salamanca, Salamanca, Spain.
Maria-Victoria
MV
Mateos
Amgen (Europe) GmbH, Zug, Switzerland.
Paul
P
Schoen
Department of Haematology, University College London, London, UK.
Kwee
K
Yong
D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D019468:Disease Management; D005060:Europe / Q000453:epidemiology; D005260:Female; D019538:Health Care Surveys; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D010820:Physicians; D010818:Practice Patterns, Physicians'
European chart review; multiple myeloma; observational; sequencing, practice patterns